Day 3 :
Keynote Forum
Gad Keren
Director, Tel Aviv Medical Centre, Israel
Keynote: Blocking the transient receptor potential vanilloid2 channel (TRPV2) may attenuate myocardial damage after myocardial infarction
Time : 09:00-09:50
Biography:
Gad Keren is the head of the department of Cardiology at Tel Aviv Medical Center and is a Professor of Cardiology at the Sackler School of Medcine
Abstract:
During the healing process after MI there an immense invasion of inflammatory cells occurs into the infarct area. We have studied the potential role of TRPV2 cation channel in recovery after MI. We shown by gene expression array study 5 days post MI that there was a significant increase in TRPV2 expression compared to sham TRPV2 channel is highly expressed in phagocytes and splenocytes and moderately in the heart. We have performed LAD ligation studies in WT mice, TRPVK/O mice and in rats. On the 3rd day by RT-PCR an increase in the level of TRPV2 was shown and validated by Western blot and Flow cytometry. Immunohistochemical staining with anti CD68 and Anti TRPV2 antibodies showed abundance of inflammatory cells on the 3rd day and also by confocal microscopy. Migration assay showed that only WT macrophages had the capacity to migrate and TRPV2 K/O mice macrophages lacked this ability. Echocardiography and pathology showed a lower reduction in LVEF in the TRPV2 K/O mice compared to control. Scar formation was smaller, and the expression of BNP from LV tissue by RTPCR was higher in the K/O mice. Adoptive transfer of WT macrophages to TRPVK/O mice resulted isworse outcome than study mice injected with KO macrphages. We are currently studying the potential role of specific antibodies to TRPV2 channel and look for a small blocking molecule.
Our data suggest TRPV2 channel blockers and reduction of activity of the channel in the setting of myocardial infarction may have a beneficial role.
Keynote Forum
Galya Atanasova
Medical University Pleven, Bulgaria
Keynote: ECG tools for cancer screening
Time : 10:20-11:10
Biography:
Galya Atanasova has completed her PhD in Cardiology from Department of Cardiology, Pulmonology and Endocrinology at Medical University Pleven, Bulgaria. She is a Cardiologist and Assistant Professor at the Department of Internal Medicine, Pleven University Hospital and General Practitioner University, Bulgaria. She specialized in General Medicine from Pleven Medical University, Bulgaria during 1993. She has attended many international events and presented her research work. She did many researches on metabolic syndrome and myocardial infarction of heart.
Abstract:
New tools for cancer screening covers a broad spectrum of new innovations. Recently professor Yoshiaki Omura found that using ECGs various cancers existing in the body can also be detected. Objectives of this study are to develop new non-invasive, safe, quick and economical method of detecting cancers. A total of 106 patients with cancer were selected from 146 participants with mean age of 65.3 years. Systolic (SBP) blood pressure, diastolic (DBP) blood pressure and BMI were measured. The 106 serum samples of patients with different tumors were evaluated for CBC. Heart rate was 77.53/min for oncology patients and 81.24/min for other people in the study. The following CBC parameters were analyzed: Red blood cell count (RBC), hemoglobin (Hb), hematocrit (Hct), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red blood cell distribution width (RDW), platelet count (PLT), mean white blood cell count (WBC) and leukocyte differential count. Spectral Analysis - MATLAB was used for the assessment of the ECGs elements. The results showed that p-waves and QRS complexes of ECG contain invisible information of specific cancers that exist in the same person. Maximum information from cancer can be found in QRS complex.